Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease
- 15 December 2010
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (24) , 7493-7497
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Investigational drugs for hepatitis CExpert Opinion on Investigational Drugs, 2009
- Serine protease inhibitors as anti-hepatitis C virus agentsExpert Review of Anti-infective Therapy, 2009
- Recent progress in the development of selected hepatitis C virus NS3·4A protease and NS5B polymerase inhibitorsCurrent Opinion in Pharmacology, 2008
- Challenges in Modern Drug Discovery: A Case Study of Boceprevir, an HCV Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionAccounts of Chemical Research, 2008
- Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitorsBioorganic & Medicinal Chemistry, 2007
- Discovery and Development of VX-950, a Novel, Covalent, and Reversible Inhibitor of Hepatitis C Virus NS3.4A Serine ProteaseInfectious Disorders - Drug Targets, 2006
- Hepatitis C and liver transplantationNature, 2005
- Hepatitis C treatment updateThe American Journal of Medicine, 2004
- Structure−Activity Study on a Novel Series of Macrocyclic Inhibitors of the Hepatitis C Virus NS3 Protease Leading to the Discovery of BILN 2061Journal of Medicinal Chemistry, 2004
- Clinical consequences of hepatitis C virus infectionReviews in Medical Virology, 2002